Publications by authors named "M G Besselink"
Introduction: Adjuvant chemotherapy improves survival in patients with resected pancreatic ductal adenocarcinoma (PDAC). The decision to initiate chemotherapy involves both patient and physician factors, decision-specific criteria, and contextual considerations. This study aimed to assess medical oncologists' views on adjuvant chemotherapy following pancreatic resection for PDAC.
View Article and Find Full Text PDFDefining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An International Multicenter Study.
Joseph R Habib Ammar A Javed Ingmar F Rompen Camila Hidalgo Salinas Anthony Sorrentino Marc G Besselink
Ann Surg Oncol
December 2024
Article Synopsis
- This study investigates early recurrence in patients with pancreatic ductal adenocarcinoma (PDAC) derived from intraductal papillary mucinous neoplasm (IPMN), aiming to identify predictors to help guide patient management.
- The research found that early recurrence is defined as occurring within 10.5 months post-surgery, affecting 38% of patients who experienced recurrence, with CA19-9 levels and N2 disease being significant predictors.
- Adjuvant chemotherapy showed a survival advantage only for high-risk patients, highlighting the importance of risk stratification for better treatment outcomes.
Background: Induction treatment may be beneficial in patients with unresectable locally advanced perihilar cholangiocarcinoma (LAPCCA). Prospective studies are currently lacking. This study aimed to assess the feasibility and efficacy of gemcitabine and cisplatin as induction treatment in patients with unresectable LAPCCA.
View Article and Find Full Text PDFArticle Synopsis
- - The study examined survival scenarios for pancreatic adenocarcinoma (PAC) patients over 16 years, highlighting best-case, typical, and worst-case survival estimates based on data from the Netherlands Cancer Registry.
- - Patients with localized PAC showed statistically significant improvements in best-case and typical survival scenarios, with gains averaging 1.54 and 0.24 months annually, respectively, while those with metastatic PAC experienced smaller but significant improvements.
- - Factors like age, aggressive treatments, and fewer comorbidities were linked to better survival outcomes, suggesting that recent advancements in care may offer hopeful prospects for PAC patients, despite small absolute survival gains.